viewNemaura Medical Inc

Nemaura Medical gives third-party apps access to its SugarBEAT glucose-monitoring data

Users will be able to access SugarBEAT-generated glucose data through their preferred mobile apps

Nemaura Medical Inc's sugarBEAT, a non-invasive continuous glucose monitoring device
SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for periods up to 24 hours

Nemaura Medical Inc (NASDAQ:NMRD) announced Thursday that it will allow third-party applications, such as diabetes management, exercise and nutrition apps, royalty-free access to its sugarBEAT continuous glucose monitor app data.

As a result, users will be able to directly access SugarBEAT-generated glucose data through their preferred mobile apps, said the company.

The move allows users greater choice over when to use the data to understand how food choices, and lifestyle factors impact glucose levels.

Shares in Nemaura were flat at $0.95 in midday trade. 

READ: Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor

“We believe integrating SugarBEAT data into the leading health and fitness apps will help to expand our target market among health-conscious consumers,” said Dr Fred Schaebsdau, who leads strategy and business development at Nemaura Medical.  

He said it will provide users with “seamless access” to their continuous glucose monitor data within a “familiar environment” to demystify how diet, sleep, stress, exercise and other lifestyle factors impact glucose levels.

Breakthrough medical technology

“Given SugarBEAT is non-invasive, we believe it is uniquely placed amongst continuous glucose monitor to appeal to the health-conscious consumer market,” said Schaebsdau.

Since sugarBEAT doesn’t require needles or insertion, it is likely to disrupt the continuous glucose monitor (CGM) device market. It will challenge entrenched players like DexCom Inc (NASDAQ:DXCM), which markets the Dexcom G6 and Abbott Laboratories' (NYSE:ABT) Libre System.

SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. The innovation of sugarBEAT lies in its groundbreaking skin-patch technology, which allows for better glucose management.

“We expect this integration will also benefit diabetics and pre-diabetics by making it easier for them to access data through their preferred diabetes, fitness or wellness app,” said Nemaura Medical CEO Faz Chowdhury. “It will also provide insurers, healthcare providers, and fitness coaches with new tools to help their patients and clients keep their glucose levels in normal range for longer.”

--(Updates share price)-- 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Nemaura Medical Inc

Price: 4.26 USD

Market: NASDAQ
Market Cap: $97.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...


Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read